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Abstract
The authors previously showed that interferon regulatory factor (IRF)4 knockout mice are protected from experimental oxa-
zolone and TNBS colitis. Here the effect of IRF4 on the expression of pro- and anti-inflammatory cytokines in TNBS colitis
and long-term CD45RBhigh transfer colitis is examined. In TNBS colitis, no differences were found in interleukin (IL)-18 and
tumor necrosis factor (TNF)-α expression between IRF4 knockout and wild-type mice. However, significant differences were
detected in IL-6 and IL-17 production. Upon treatment with hyper-IL-6, IRF4–/– mice lost their protective properties towards
TNBS application. Hyper-IL-6 application induced IL-6 mRNA, but not IL-17 mRNA expression, suggesting that IL-6 defi-
ciency is not primarily responsible for the lack of IL-17 production. T-bet and GATA-3 mRNA expressions were not affected
upon IL-6 application. In transfer colitis, colonic cytokine mRNA analysis revealed a reduced production of IL-6 in IRF4–/–
reconstituted mice in the long-term course. In contrast, several other cytokines did not differ between the two groups (e.g.
TNF-α and IL-10). Measurement of supernatants from splenic mononuclear cells revealed a significant difference in IL-6 and
IL-17 production between the two groups. These findings suggest that IRF4 selectively regulates cytokine gene expression in
chronic inflammation. IRF4 therefore emerges as an attractive target for the therapy of chronic intestinal inflammation.
Blocking IRF4 might be an interesting option to modulate inflammation in the advanced state of inflammation.
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INTRODUCTION
Inflammatory bowel diseases are driven by a mucos-
al cytokine imbalance resulting from a misled immune
response influenced by luminal antigens and a defective
mucosal barrier in genetically susceptible individuals
(Macdonald and Monteleone 2005; Mudter and
Neurath 2003; Podolsky 2002; Sartor 2004; Shanahan
2002; Wehkamp et al. 2005). To characterize the diverse
aspects and cytokine interactions of the immune
response in intestinal inflammation, several experimen-
tal models have been established (Blumberg et al. 1999;
Strober et al. 2002). Such in vivo studies have shown that
interleukin (IL)-6 signaling plays a pivotal role in
inflammatory bowel diseases. In intestinal inflamma-
tion, IL-6 transsignaling contributes to enhanced T-cell
survival and accumulation of activated T cells in the
lamina propria (Atreya et al. 2000; Mudter et al. 2002). 
The transcription factor interferon regulatory factor
(IRF)4 is a member of the IRF family of transcription
regulators. Previous in vivo studies of IRF4 function
pointed out its critical role in T helper (Th)2 differenti-
ation (Lohoff et al. 2002). IRF4-deficient (–/–) and
IRF4+/– mice were infected with Leishmania major pro-
mastigotes in their footpads. One week later, regional
lymph node cells were isolated and re-stimulated in
vitro. The IRF4+/– mice exhibited IL-4 and interferon
(IFN)-γ secretion. In contrast, lymph node cells from
the IRF4–/– mice produced neither IL-4 nor IFN-γ.
Furthermore, in vitro differentiation studies showed
strongly impaired Th1 and Th2 cytokine responses of
IRF4–/– T cells. It was found that IL-4-dependent Th2
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differentiation was due to the inability of IRF4–/– lym-
phocytes to upregulate GATA-3 expression. The ability
to undergo Th2 differentiation could be restored by
retroviral overexpression of GATA-3. Furthermore,
a strong synergism between NFATc2 and IRF4 in IL-4
gene transcription was reported (Rengarajan et al.
2002). Very recently, IRF4 was also attributed to play
a role in IL-17 production (Brustle et al. 2007). The
authors showed that IRF4-deficient mice did not devel-
op experimental autoimmune encephalomyelitis and
that T helper cells from such mice failed to differentiate
into Th17 cells.
In previous studies we could show that IRF4 defi-
ciency protected from experimental colitis due to
reduced expression of IL-6. In this study the aim was to
analyze the influence of IRF4 deficiency on cytokine
expression in long-term colitis. 
MATERIALS AND METHODS
Animals and induction of colitis
The TNBS colitis model was previously described
(Boirivant et al.1998; Neurath et al.1995). Transfer col-
itis was performed as described by Morrissey et al.
Powrie et al. (Morrissey et al. 1993; Powrie et al. 1993).
In brief, CD4+ CD45RBhigh T cells were sorted by flow
cytometry (FACScalibur, BD) and 5×105 cells were
intraperitoneally transferred into Rag2–/– mice. T cells were
derived either from IRF4–/– or C57BL/6 donors. To modu-
late colitis activity, mice were given 1 µg hyper-IL-6
(hyper-IL-6 consists of human IL-6 and the human sIL-
-6R covalently connected by a flexible peptide chain) by
intraperitoneal injection (obtained from Prof. Rose-John,
University of Kiel, Germany). The injection was made 7
days after skin sensitization with TNBS just before intrarec-
tal administration of the hapten reagents. 
Preparation of gut tissues
The murine colon was divided in a proximal and
a distal piece. Colon pieces were snap frozen and either
homogenized or embedded in OCT compound to assess
cryosections. Paraffin-embedded sections were used to
perform hematoxylin and eosin staining for histological
scoring. Furthermore, one piece of each part (proximal
and distal) was snap-frozen to isolate mRNA. 
Histological analysis of colon cross-sections
and endoscopy
Tissues were removed from colitic mice and sections
were made and stained with hematoxylin and eosin. The
degree of inflammation on the microscopic cross-sec-
tions of colon was graded semiquantitatively on a scale
of 0–6, or 0–15 in the case of transfer colitis, by the same
pathologists blinded to the sample’s identity, as
described before (Mudter et al. 2008). 
To perform experimental endoscopy, the mice were
anesthetized using an intraperitoneal injection of aver-
tine (Sigma Chemical Co., St. Louis, MO, USA). Mouse
endoscopy was performed using a miniature endoscope
(scope outer diameter: 1.9 mm), a xenon light source,
a triple chip camera, and an air pump (all from Karl
Storz, Tuttlingen, Germany). The endoscopic procedure
was viewed on a color monitor and digitally recorded on
tape (DSR-20MDP; Sony, Cologne, Germany).
Endoscopic colitis scores were based on the
observed signs of inflammation. The modified murine
endoscopic index of colitis severity consisted of five
parameters: thickening of the colon wall, changes in the
normal vascular pattern, presence of fibrin, mucosal
granularity, and stool consistency. Endoscopic screening
was performed for each parameter (score between 0 and
3), leading to a cumulative score between 0 and 15.
Healthy mice usually have a score between 0 and 3
(Wirtz et al. 2002).
Cell isolation and purification of spleen 
mononuclear cells
Spleen mononuclear cells were isolated from freshly
obtained specimens from healthy B6 mice. Erythrocytes
were removed from the spleen cell suspension by hypo-
tonic lysis in ammonium chloride and potassium chlo-
ride buffer. The MACS system (Miltenyi, Germany) was
used to isolate CD4+ T cells. The cells were cultured in
complete Roswell Park Memorial Institute medium in
a humidified atmosphere with 5% CO2 in a 37°C incu-
bator in the presence or absence of hamster antibodies
against mouse CD3 and CD28 (CD3, clone 145-2C11, 2
mg/ml; CD28, clone 37.51, 0.5 mg/ml; PharMingen, San
Diego, CA, USA).
Th17 differentiation
1×106/well MACS-purified CD4+ T cells were cultured
in 24-well plates containing plate-bound anti-CD3 (5
mg/ml) and soluble anti-CD28 (1 mg/ml). The cultures
were supplemented with 20 ng/ml IL-6 (eBioscience) or
hyper-IL-6, 1 ng/ml IL-1β, 1 ng/ml tumor necrosis factor
(TNF)-α, and 5 ng/ml transforming growth factor-β
(Preprotech). For flow cytometry and sandwich ELISA
the cells were analyzed on day 4. 
Cytokine measurement
The cytokine concentration was measured in the
supernatants of either mononuclear spleen cells or iso-
lated CD4+ T cells. Quantification was performed using
a multiple cytokine measurement kit and flow cytometry
according to the manufacturer’s instructions
(BenderMed Systems). IL-6 and IL-17A were also mea-
sured using enzyme-linked immunosorbent assay kits
(ELISA Kits; eBioscience, San Diego, CA, USA). The
cells were cultured and stimulated for 24 or 48 h as pre-
viously mentioned using anti-CD3 and anti-CD28 (CD3,
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clone 145-2C11, 2 µg/ml; CD28, clone 37.51, 0.5 µg /ml;
PharMingen, San Diego, CA, USA). 
RT-PCR and real-time PCR
A sample of the distal part of the colon was used for
RNA isolation. Colonic tissue was disrupted and
homogenized by bead-milling in RLT Plus Buffer®
(Qiagen, Hamburg, Germany), containing denaturing
guanidine-isothiocyanate and β-mercaptoethanol. RNA
was purified by extraction with RNeasy® Plus Mini Kits
(Qiagen, Hamburg, Germany). 
Reverse transcription (RT) was performed by mix-
ing 1 µg of RNA solution, deoxynucleoside triphosphate
(dNTP) Mix (PEQLAB Biotechnology GmbH,
Erlangen, Germany), random hexamer primer
(Invitrogen, Karlsruhe, Germany), and oligo(dT)
(MWG-BIOTECH AG, Ebersberg, Germany) and
incubating the solution (13 µl) for 5 min at 65°C. Then 7
µl of a solution containing 5X First-Strand Buffer
(PEQLAB Biotechnology GmbH, Erlangen, Germany), 40
U of RNaseOUT™ (Eppendorf, Wesseling-Berzdorf,
Germany), and dithiothreitol (DTT) (Invitrogen, Karlsruhe,
Germany) was added. The mixed contents were incubated
for 2 min at 25°C. Two hundred units of SuperScript™ RT
II RT (PEQLAB Biotechnology GmbH, Erlangen,
Germany) was added and the tubes were incubated for 10
min at 25°C and then for 50 min at 42°C. Finally the tubes
were heated to 70°C for 15 min. cDNA was mixed with
REDTaq™ ReadyMix™ PCR Reaction Mix (Sigma-
-Aldrich CHEMIE Gmbh, Steinheim, Germany) and 24–35
cycles of PCR were performed in a thermal cycler. The
PCR products were visualized by agarose gel electrophore-
sis. Primer pairs were used as previously described
(Autenrieth et al. 1997) except that for IL-6 (sense mIL6
e2s GAG AGG AGA CTT CAC AGA GGA T, antisense
mIL6 e4a GCT TAG GCA TAA CGC ACT AGG TT).
For real-time PCR, total RNA from a murine colon
specimen was extracted using an RNeasy Mini Kit
(Qiagen, Hamburg, Germany). One µg of total RNA
was reverse transcribed using an oligo-dT primer. Real-
-time PCR analysis for quantification of the expressions
of IL-6, IL-17, GATA-3, and T-bet and β-actin mRNAs
was performed in duplicate on an iCycler (Bio-Rad
Laboratories) using the ABsolute SYBR Green
Fluorescein Kit (Abgene, Epsom, UK). The primer sets
for these experiments were purchased from QuantiTect
(Qiagen, Hamburg, Germany). The sequences for IL-17
were: IL-17 sense: GGACTTCCTCCAGAATGT and
IL-17 antisense: TCAGGACCAGGATCTCTT. The
relative increase in reporter fluorescent dye emission
was monitored. The level of cytokine mRNA relative to
actin was calculated using the formula: 
Relative cytokine mRNA expression =
2^[ct(cytokinecontrol)–ct(cytokinetreated)+ct(Actintreated)–
–ct(Actincontrol)]
where ct is the number of the cycle in which emission
exceeds an arbitrarily defined threshold.
Immunohistochemistry
Immunofluorescence of the cryosections was per-
formed using the TSA Cy3 system (PerkinElmer,
Waltham, MA, USA) and a fluorescence microscope
(Olympus, Hamburg, Germany) using primary antibod-
ies specific to CD4 (Santa Cruz Biotechnology,
Heidelberg, Germany), CD11c, and myeloperoxidase
(MPO, BD Biosciences). Before examination, the nuclei
were counterstained with Hoechst 3342 (Invitrogen
Molecular Probes, Karlsruhe, Germany).
Statistical evaluation
All experiments were carried out at least in tripli-
cate. The statistical significance of the evaluated data
was tested using the Mann-Whitney U-test and
Student’s t-test. Results were considered statistically sig-
nificant when p values were <0.05. Results are
expressed as mean values (±SD or ±SEM). The error
bars in the histograms represent the standard deviations
or standard errors of the mean, as indicated.
RESULTS
Increased IL-6 production in the colons of TNBS-treated
wild-type mice compared with TNBS-treated IRF4–/– mice
In the first series of experiments we evaluated TNBS
colitis. In contrast to the our previously performed
TNBS colitis experiments (Mudter et al. 2008), the mice
were evaluated on day 5 instead of days 3 and 4. Thus we
sacrificed the mice on day 5. The colon from each
mouse was removed and mRNA was isolated to analyze
cytokine expression in the IRF4-deficient and wild-type
mice using semiquantitative PCR. Interestingly, where-
as equal levels of IL-18 mRNA and TNF-α mRNA were
detected in the colons of the wild-type and knockout
mice, IL-6 mRNA levels in the lamina propria were
much higher in the colitic wild-type mice than in the
TNBS-treated IRF4–/– mice (Fig. 1A). 
Administration of hyper-IL-6 exerts a long-lasting 
proinflammatory effect on colitis activity 
in IRF4-deficient mice
To assess whether the reduced mucosal IL-6 pro-
duction in IRF4–/– mice was relevant in vivo, we next
injected the designer protein hyper-IL-6 (IL-6/sIL-6R)
intraperitoneally into TNBS-treated IRF4–/– mice (Fig.
1B). This completely blocked the protective effect of
IRF4–/– deficiency in TNBS-induced colitis and induced
weight loss comparable to that of the TNBS-treated
wild-type mice. The effect of hyper-IL-6 was long lasting
because the hyper-IL-6-treated colitic IRF4-deficient
mice continuously lost weight. In contrast, the TNBS-
-treated IRF4-deficient mice without hyper-IL-6 treat-
ment gained weight on days 4 and 5. We also performed
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an endoscopic analysis of colitis severity (Fig. 1C).
Whereas the colonic mucosa of the IRF4–/– mice was
unaffected, the wild-type mice showed severe inflamma-
tion of the mucosa upon TNBS application. The histo-
logical assessment of colitis severity consistently showed
significantly higher inflammation scores in the wild-type
mice than in the IRF4-deficient mice and the mean
score in the latter was similar to that of the healthy
untreated control mice. In contrast, the administration
of hyper-IL-6 led to severe mucosal lesions, including
large ulcers in the TNBS-treated IRF4–/– mice (Fig. 1D). 
Decreased production of IL-6 and IL-17 in TNBS-treated
IRF4-deficient mice
To clarify the proinflammatory mechanisms induc-
ing colitis in the protected IRF4 phenotype, we focused
on several proinflammatory factors. On the one hand we
evaluated TNBS-treated IRF4–/– and wild-type mice and
on the other the effect of hyper-IL-6 application in the
otherwise protected IRF4-deficient mice on the expres-
sions of proinflammatory factors in the long-term
course.
Interestingly, there was no difference in mRNA
expression of the Th1 and Th2 master regulator tran-
scription factors T-bet and GATA-3 between the
IRF4–/– and wild-type mice upon TNBS administration
in the long term course (Fig. 2A and B). The application
of hyper-IL-6 had no influence on T-bet and GATA-3
expression. Importantly, hyper-IL-6 itself induced IL-6
production in the TNBS-treated IRF4-deficient mice
(Fig. 2C). Although IL-6 mRNA production was lower
than that in the TNBS-treated wild-type mice, it was sig-
nificantly induced compared with the TNBS-treated
IRF-deficient mice without hyper-IL-6 administration
(Fig. 2C). The analysis of IL-17 expression revealed
a significant difference between TNBS-treated IRF4-
-deficient mice and wild-type mice (Fig. 2D). In the
Fig. 1. Evaluation of TNBS coliis. (A) The mRNA expressions of various proinflammatory cytokines in the colons of TNBS-treated and
untreated IRF4-deficient and wild-type mice were analyzed by semiquantitative PCR. Whereas no differences in the expressions of the
proinflammatory cytokines TNF-α and IL-18 were noted between the groups, IL-6 mRNA expression was strongly induced in the wild-type,
but not in the IRF4-deficient mice upon TNBS administration. (B) IRF4-deficient mice and wild-type control mice were treated by intrarec-
tal administration of the hapten reagent TNBS followed by monitoring of body weight. TNBS-treated IRF4–/– mice lost significantly
(p<0.05) less weight than the wild-type mice. To determine the functional role of IL-6 signaling for the effects of IRF4 on TNBS colitis
activity in vivo, the designer fusion protein hyper-IL-6 (IL-6/sIL-6R) was intraperitoneally administered to TNBS-treated IRF4-deficient
mice. This group showed similar weight loss to the TNBS-treated IRF4+/+ mice. One representative experiment out of three is shown
(IRF4+/+ plus TNBS, n=8; IRF4–/– plus TNBS, n=9; IRF4–/– plus TNBS and hyper-IL-6, n=6; IRF4–/– control, n=4). (C) TNBS-treated
IRF4–/– mice exhibited severe inflammation upon hyper-IL-6 treatment that was indistinguishable from colitis in the wild-type control mice.
High-resolution mini-endoscopy consistently demonstrated severe mucosal inflammation upon hyper-IL-6 treatment in the IRF4 knockout
mice that was comparable to the colitis activity in the wild-type mice. Representative histological and endoscopic images from the different
groups of mice in TNBS-induced colitis are shown. (D) Statistical evaluation of histological and endoscopic results corresponding to the pic-
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IRF4–/– mice, IL-17 expression was strikingly reduced
compared with that in the wild-type mice. Furthermore,
we found that IL-17 was not induced upon hyper-IL-6
administration, suggesting that the underlying mecha-
nism is an intrinsic defect in IL-17 production. 
IRF4–/– reconstituted immunodeficient RAG2–/– mice are
protected from colitis, but exhibit “minimal” disease in
the long-term course
To study the cytokine pattern in a second T cell-
-dependent experimental colitis model in the long-term
course, we determined the effects of IRF4 in a transfer
colitis model in which CD4+ CD45RBhigh T cells are
adoptively transferred into immunocompromised hosts.
Splenic CD45RBhigh CD4+ cells were isolated either
from wild-type or IRF4–/– mice. The cells were then
intraperitoneally injected into immunodeficient
RAG2–/– mice. Within 20 days the RAG mice reconsti-
tuted with CD45RBhigh CD4+ T cells from wild-type
mice showed diarrhea and lost body weight (Fig. 3A). In
contrast, RAG2–/– mice reconstituted with CD45RBhigh
CD4+ T cells from IRF4–/– mice gained weight (Fig. 3A).
Interestingly, IRF4–/– reconstituted RAG2–/– mice and
RAG2–/– control mice exhibited no differences in body
weight until day 100. At this time the RAG2–/– control
mice continued to gain weight, whereas the IRF4–/–
reconstituted mice stopped gaining weight. However,
the difference in body weight was significant between
the wild-type reconstituted mice and the IRF4–/– recon-
stituted mice. Colonoscopy of the mice in the latter
group consistently revealed no signs of mucosal inflam-
mation, whereas the RAG2–/– deficient mice reconstitut-
ed with wild-type CD45RBhigh CD4+ T cells exhibited
severe mucosal inflammation (Fig. 3B, C). Moreover,
the latter mice showed a significantly higher histological
score of colitis activity than the former (Fig. 3B). 
Reduced IL-6 and IL-17 production in RAG knockout
mice reconstituted with IRF4–/– T cells in the long-term
course
We next analyzed cytokine expression in the RAG2–/–
recipient mice reconstituted with CD45RBhigh CD4+
cells from either wild-type or IRF4–/– mice. Whereas the
expressions of various proinflammatory cytokines, such
as IL-4, IFN-γ, IL-1α, and IL-1β, were reduced in the
IRF4–/– reconstituted RAG2–/– mice compared with the
wild-type reconstituted RAG2–/– mice, little or no
changes in the expressions of IL-10 and TNF-α were
noted (Fig. 4A). However, further analysis of cytokine
expression in the gut revealed a marked reduction in
mucosal IL-6 expression (Fig. 4A) in the RAG knockout
mice reconstituted with IRF4-deficient cells compared
with the mice given wild-type T cells. Furthermore, iso-
lated spleen cells derived from the IRF4–/– reconstituted
RAG2–/– mice showed significantly lower levels of IL-6
and IL-17 production than cells from the wild-type
reconstituted RAG2–/– mice (Fig. 4B). 
DISCUSSION
In this study we analyzed two experimental models
of colitis in its long-term course. TNBS-treated mice
were evaluated on day 5 and CD45RBhigh reconstituted
mice were evaluated on day 119. In the latter case the
time span was increased fivefold compared with the
evaluation procedure that we usually use in transfer col-
itis (15 to 20 days). In prior studies, TNBS colitis was
evaluated on days 3 or 4. Compared with these studies
(Mudter et al. 2008), TNBS-treated IRF4–/– mice tend-
ed to recover from inflammation on days 4 and 5 in our
current experiments. Since we know that IL-6 might
play a role in acute and chronic inflammation, we aimed



















































































































Fig. 2. Measurement of characteristic T-cell cytokines/transcrip-
tion factors in TNBS-treated wild-type and IRF4–/– mice. The
mRNA expression of the master regulator of Th1 cells T-bet as
well as the mRNA expression of GATA-3 in the colons of the
TNBS-treated IRF4-deficient and the wild-type mice were ana-
lyzed by quantitative PCR (n=6 per group). We found no signifi-
cant differences in the expression levels of T-bet and GATA-3
between the groups (A, B). Upon administration of hyper-IL-6,
neither T-bet nor GATA-3 mRNA was induced (A, B, gray bar).
IL-6 mRNA was strongly reduced in the IRF4–/– mice compared
with the wild-type mice (C). The same effect was observed analyz-
ing IL-17 mRNA expression. The application of hyper-IL-6
induced IL-6 expression, but not IL-17 (D, gray bar). 
** Significance between the groups (p<0.01).
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late phase of colitis (Atreya et al. 2000). Indeed, we
found that IL-6 was significantly increased in TNBS-
-treated wild-type mice compared with IRF4-deficient
mice on day 5. To focus on Th1 regulatory and counter-
-regulatory mechanisms, we analyzed GATA-3 and T-
-bet expression. The transcription of the GATA-3 gene
may be induced by IRF4 (Lohoff and Mak 2005) and
strongly contributes to Th2 differentiation. Thus we
measured GATA-3 expression and could show that in
Th1 colitis, independent of IRF4 deficiency, GATA-3
expression is not differentially regulated. The transcrip-
tion factor T-bet is known to regulate early Th1 respons-
es in experimental colitis (Neurath et al. 2002). It was
shown that T-bet is overexpressed before colitis symp-
toms occur and that overexpression of T-bet may accel-
erate experimental colitis. In this study it was found that
retroviral transduction of T-bet in CD62L+ CD4+
T cells exacerbated colitis in reconstituted SCID mice.
In contrast, T-bet-deficient T cells failed to induce coli-
tis in adoptive transfer experiments, suggesting that
overexpression of T-bet is essential and sufficient to
promote early Th1-mediated colitis in vivo. In our cur-
rent studies we found that neither T-bet nor GATA-3,
the master Th2 transcription factor, were differentially
expressed in IRF4-deficient and wild-type mice in long-
term colitis, suggesting that IL-6 might dominate chron-
ic inflammation (Neurath et al. 2002). 
The lack of IL-6 production and the consecutive pro-
tective phenotype of IRF4–/– mice could be reconstitut-
ed by administration of hyper-IL-6. Interestingly, this
effect persisted after one single hyper-IL-6 application.
This time span is longer than the half-life of this protein.
This long-lasting effect demonstrates that IL-6 and its
soluble receptor are effective fomenters of inflamma-
tion. Focusing on the underlying mechanism, there is
great evidence that IL-6 and its soluble receptor itself
induce IL-6 production, thus promoting inflammation
at least to a certain extent. Since it is known that IL-6
contributes to the differentiation of Th17 cells, which in
turn may activate IL-6 signaling (Ivanov et al. 2006;
Mudter and Neurath 2007; Ogura et al. 2008), we ana-
lyzed the effect of hyper-IL-6 application on IL-17
induction. Surprisingly, IL-17 was not induced in IRF4–/–
mice upon hyper-IL-6 treatment, suggesting that there
is an intrinsic defect in IL-17 production in IRF4-defi-
cient mice. The lack of IL-17 in IRF4-deficient mice was
previously described (Brustle et al. 2007). However, the
molecular mechanism is still unclear, although there is
strong evidence that IRF4 directly activates IL-17 pro-
duction on the transcriptional level (Mudter et al.,
unpublished data). Previous studies by other groups
strongly suggest that IL-17 is an important mediator of
inflammation (Brustle et al. 2007; Ivanov et al. 2006;
Yen et al. 2006). It was also postulated that IL-17a trig-
gers a positive-feedback loop of IL-6 signaling (Ogura et
al. 2008). These data highlight the important role of IL-6
as both an inducer and an effector cytokine of Th17
cells. We have shown that the lack of IL-17 is not a “con-
ditio sine qua non” in chronic long-term colitis because
it is sufficient to reconstitute the lack of IL-6 to induce
colitis in otherwise protected IRF4-deficient mice.
Importantly, it would be necessary to reconstitute IL-17
production via application of IL-17 into IRF4–/– mice to
observe the proinflammatory effect of IL-17 (manu-
script in preparation). With regard to therapeutic
options it might be helpful to attribute the duration of
Fig. 3. Protective effect of IRF4–/– in long-term transfer colitis. (A) CD45RBhigh CD4+ T cells from wild-type or IRF4–/– mice were adoptively
transferred into immunodeficient RAG2–/– mice. RAG2–/– mice reconstituted with wild-type T cells developed severe colitis accompanied by
weight loss (red curve). After initial weight loss from day 13 to day 17, body weight remained static in the state of chronic inflammation. In
contrast, mice given IRF4–/– T cells were completely protected and even gained body weight (green curve) similar to RAG2–/– control mice
(blue curve). The differences between the two reconstituted groups were significant at days 13 to 17 (p<0.01) and from day 25 until evalu-
ation of the mice at day 119. (n=9 mice per group, three independent experiments). (B) Histological scoring revealed significantly reduced
colitis activity in IRF4–/– reconstituted mice compared to IRF4+/+ reconstituted mice (p<0.01). (C) Endoscopy consistently showed an
inflamed mucosa in the RAG2 knockout mice given wild-type T cells, whereas little or no inflammation was noted in the RAG2–/– mice
reconstituted with IRF4-deficient T cells. 
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disease or current stage of the immune response to dif-
ferent cytokine profiles. Thus a stage-specific antagonis-
tic therapy might be designed. 
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